SARS-CoV-2 Serology for the Rapid Diagnosis of COVID-19
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1074
Special Issue Editor
Special Issue Information
Dear Colleagues,
Serology tests, or antibody tests, use a variety of techniques to detect antibodies from the blood, revealing whether a person has been exposed to a particular pathogen by looking at their immune response.
Serological tests also vary according to the viral antigens measured. Spike proteins (S) and nucleocapsid proteins (N) are the viral antigens used to detect antibodies for SARS-CoV-2, with the intended use to identify whether an individual was recently or previously infected by the virus. These serology tests can be broadly categorized by their readout platforms used to detect SARS-CoV-2 antibodies: enzyme immunoassay, high-throughput; enzyme immunoassay, medium-throughput; lateral flow assay; and total neutralizing antibodies.
A reliable serology test to rapidly quantify neutralizing antibody levels in a high-throughput manner is essential for diagnosis, vaccine development, and antiviral development—especially once a minimal threshold of nAb has been defined for disease prevention in the near future. Even in a postvaccination era, serology tests will remain critical for studying both individuals’ and the community's protective immunity to safeguard public health around the world. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review to highlight the new trends in serology tests for COVID-19.
Dr. Jesus Alberto Silvas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- SARS-CoV-2
- serology test
- antibody test
- diagnostic test
- vaccination
- immunization
- antibody response
